Atherosclerosis and Lipoproteins |
From the Unité dExpression des Gènes Eucaryotes, Institut Pasteur (L.V., N.B., M.A.O., M.M.Z., A.O.), Paris, France; U 325 Inserm Institut Pasteur (G.C., J.N., J.-C.F.), Lille, France; Rhone-Poulenc Rorer (N.D.), Vitry sur Seine, France; Institut National de la Recherche Agronomique (A.O.) Jouy-en-Josas, France; and St. Bartholomews and the Royal London School of Medicine and Dentistry (M.N.N., N.E.M.), London, UK.
Correspondence to Alberto Ochoa, Unité dExpression des Gènes Eucaryotes, Institut Pasteur, 28 rue du Dr. Roux, 75724, Paris cedex 15, France. E-mail aochoa{at}pasteur.fr
AbstractThe apolipoprotein (apo)A-I/C-III/A-IV gene cluster is involved in lipid metabolism and atherosclerosis. Overexpression of apoC-III in mice causes hypertriglyceridemia and induces atherogenesis, whereas overexpression of apoA-I or apoA-IV increases cholesterol in plasma high density lipoprotein (HDL) and protects against atherosclerosis. Each gene has been studied alone in transgenic mice but not in combination as the entire cluster. To determine which phenotype is produced by the expression of the entire gene cluster, transgenic mice were generated with a 33-kb human DNA fragment. The results showed that the transgene contained the necessary elements to direct hepatic and intestinal expression of the 3 genes. In the pooled data, plasma concentrations were 257±9, 7.1±0.5, and 1.0±0.2 mg/dL for human apoA-I, apoC-III, and apoA-IV, respectively (mean±SEM). Concentrations of these apolipoproteins were higher in males than in females. Human apoA-I and apoC-III concentrations were positively correlated, suggesting that they are coregulated. Transgenic mice exhibited gross hypertriglyceridemia and accumulation of apoB48containing triglyceride-rich lipoproteins. Plasma triglyceride and cholesterol concentrations were correlated positively with human apoC-III concentration, and HDL cholesterol was correlated with apoA-I concentration. In an apoE-deficient background, despite being markedly hypertriglyceridemic, cluster transgenic animals compared with nontransgenic animals showed a 61% reduction in atherosclerosis. This suggests that apoA-I and/or apoA-IV can protect against atherosclerosis even in the presence of severe hyperlipidemia. These mice provide a new model for studies of the regulation of the 3 human genes in combination.
Key Words: transgenic mice hypertriglyceridemia cholesterol lipoproteins atherosclerosis
This article has been cited by other articles:
![]() |
J. W. Heinecke The HDL proteome: a marker-and perhaps mediator-of coronary artery disease J. Lipid Res., April 1, 2009; 50(Supplement): S167 - S171. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Mezdour, G. Larigauderie, G. Castro, G. Torpier, J. Fruchart, M. Nowak, J.-C. Fruchart, M. Rouis, and N. Maeda Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency J. Lipid Res., May 1, 2006; 47(5): 912 - 920. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shepherd Raising HDL-cholesterol and lowering CHD risk: does intervention work? Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F15 - F22. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Merkel, B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase J. Biol. Chem., June 3, 2005; 280(22): 21553 - 21560. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gao, Y. Wei, Y. Huang, D. Liu, G. Liu, M. Wu, L. Wu, Q. Zhang, Z. Zhang, R. Zhang, et al. The Expression of Intact and Mutant Human apoAI/CIII/AIV/AV Gene Cluster in Transgenic Mice J. Biol. Chem., April 1, 2005; 280(13): 12559 - 12566. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Baroukh, E. Bauge, J. Akiyama, J. Chang, V. Afzal, J.-C. Fruchart, E. M. Rubin, J. Fruchart-Najib, and L. A. Pennacchio Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice Arterioscler Thromb Vasc Biol, July 1, 2004; 24(7): 1297 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-m. R. Wong, E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels Circ. Res., May 16, 2003; 92(9): 969 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gervais, S. Pons, A. Nicoletti, C. Cosson, J.-F. Giudicelli, and C. Richer Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 183 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ostos, D. Recalde, N. Baroukh, A. Callejo, M. Rouis, G. Castro, and M. M. Zakin Fructose Intake Increases Hyperlipidemia and Modifies Apolipoprotein Expression in Apolipoprotein AI-CIII-AIV Transgenic Mice J. Nutr., May 1, 2002; 132(5): 918 - 923. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |